Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Charcot-Marie-Tooth disease type 1B (CMT1B; MONDO:0007307) is an autosomal dominant demyelinating neuropathy caused by pathogenic variants in the MPZ gene (HGNC:7225), which encodes the myelin protein zero (P0) adhesion molecule critical for peripheral myelin compaction. P0 mediates homophilic adhesion between Schwann cell membranes, and MPZ mutations disrupt myelin ultrastructure, leading to segmental demyelination, onion-bulb formation, and slowed nerve conduction.
Genetic studies have identified over 120 distinct MPZ variants in more than 100 unrelated probands, including missense, frameshift, splice-site, and gene-duplication alleles segregating in multi-generation families with complete penetrance and de novo cases (PMID:7693129; PMID:7694726). Segregation analysis across >70 pedigrees and the observation of de novo variants such as c.292C>T (p.Arg98Cys) confirm autosomal dominant inheritance and support definitive clinical validity.
The variant spectrum encompasses extracellular domain substitutions (e.g., c.292C>T (p.Arg98Cys) in a sporadic Japanese case with kyphoscoliosis and motor delay (PMID:9168174)), transmembrane glycine-zipper disruptions (e.g., p.Gly163Arg), cytoplasmic frameshifts (e.g., c.156_157del (p.Phe52Leu)), splice-altering substitutions, and rare duplications. Recurrent variants include Thr124Met observed in multiple European cohorts, suggesting a mutation hotspot rather than a single founder effect.
Genotype–phenotype correlations reveal that extracellular domain variants introducing charged residues or disrupting disulfide bonds cause early-onset, severe dysmyelinating neuropathies via endoplasmic reticulum (ER) retention and unfolded protein response (UPR) activation (e.g., Ser63del activates UPR), whereas certain cytoplasmic and late-onset variants produce milder demyelination or axonal degeneration by partial loss-of-function and disrupted SC-axon interactions.
Functional assays in CHO, HeLa, PC12, and Schwann-like cells demonstrate that MPZ mutants exhibit defective membrane trafficking, dominant-negative adhesion, or ER aggregation (PMID:11935267; PMID:16252242). Transgenic mouse models expressing P0sub (Ile106Leu) recapitulate tomaculous dysmyelination, while Mpz+/- null mice exhibit mild sensory neuropathy, confirming both gain- and loss-of-function mechanisms and offering preclinical platforms for therapeutic testing.
Collectively, the robust genetic and experimental concordance establishes a Definitive MPZ–CMT1B association, justifying routine MPZ sequencing and copy-number analysis in patients with demyelinating neuropathy. The clinical utility of MPZ testing is underscored by precise prognosis, genetic counseling, and emerging targeted therapies.
Gene–Disease AssociationDefinitiveOver 120 distinct MPZ variants in >100 unrelated probands across >70 families, with consistent autosomal dominant segregation and concordant functional data Genetic EvidenceStrongOver 120 variants in >100 probands, including de novo cases and multi-generation segregation analyses Functional EvidenceStrongMultiple in vitro and in vivo models demonstrating dominant-negative and haploinsufficiency mechanisms via ER retention, UPR activation, and rescue experiments |